diindolylmethane
Small moleculeexperimental
3,3′-Diindolylmethane (DIM) is a compound derived from the digestion of indole-3-carbinol, found in cruciferous vegetables, such as broccoli, Brussels sprouts, cabbage and kale. It and its parent compound – indole-3-carbinol – are under laboratory research to determine their possible biological properties, particularly in anti-cancer mechanisms. DIM is sold as a dietary supplement. — Wikipedia
Clinical trial activity
18 trials · 22 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Sep 1, 2000 (NCT00212381)
Timeline
Indications
Mechanism of action
- NF-kappaB inhibitor alphaINHIBITOR
NFKBIA inhibitor
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- Wikipedia3,3'-Diindolylmethane ↗
Also known as
- 3,3'-diindolylmethane
- 3,3'-diindolylmethane
- diindolylmethane
- diindolylmethane
- diindolylmethane
- di-indolylmethane
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04292236 | N/A | Feb 22, 2019 | University of London |
| NCT03718611 | Phase 1 | Oct 22, 2018 | Boryung Pharmaceutical Company, Kyungpook University |
| NCT03152097 | N/A | Jun 1, 2017 | University of Pittsburgh |
| NCT02483624 | Phase 1 | Jan 1, 2016 | Northwell Health |
| NCT02197000 | N/A | Sep 1, 2014 | Technion University, Tel Aviv University |
| NCT01612910 | Phase 2 | Jun 1, 2012 | National Cancer Institute (NCI), Wayne State University |
| NCT01391689 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2011 | National Cancer Institute (NCI), University of Arizona |
| NCT00888654 | Phase 2 | Aug 1, 2009 | National Cancer Institute (NCI), Wayne State University |
| NCT01022333 | Phase 1 | Jul 1, 2009 | BioResponse, University of Toronto |
| NCT00591305 | N/A | Sep 1, 2007 | Boston University, National Institute on Deafness and Other Communication Disorders (NIDCD) |
| NCT00450229 | Phase 1 | Feb 1, 2007 | National Cancer Institute (NCI), University of Wisconsin |
| NCT01846364 | Early Phase 1 (Phase 1) | Nov 1, 2006 | The New York Eye & Ear Infirmary |
| NCT00392652 | Phase 1 | Nov 1, 2006 | National Cancer Institute (NCI), University of Kansas |
| NCT02525159 | Phase 3 | Aug 1, 2006 | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes |
| NCT00305747 | Phase 1 | Aug 1, 2005 | National Cancer Institute (NCI), Wayne State University |
| NCT00462813 | Phase 3 | Oct 1, 2004 | Barts & The London NHS Trust, University of London |
| NCT00784394 | Phase 1 | Apr 1, 2004 | National Cancer Institute (NCI), University of Kansas |
| NCT00212381 | Phase 3 | Sep 1, 2000 | Cornell University, New York Presbyterian Hospital, New York University |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (22)
22 organizations
Page 1 / 2